Appendix 1: Acceptable intakes established for N-nitrosamines
Submitted by Anonymous (not verified) on 2 May 2024 - 15:12
Appendix 1: Acceptable intakes established for N-nitrosamines
Herbal medicinal product: Malvae sylvestris flosArray, F: Assessment finalised
Submitted by Anonymous (not verified) on 2 May 2024 - 14:28
Herbal medicinal product: Malvae sylvestris flosArray, F: Assessment finalised
Addendum to EMA/CHMP/CVMP/QWP/17760/2009 Rev 3: Defining the Scope of an NIRS Procedure
Submitted by Anonymous (not verified) on 2 May 2024 - 13:50
Addendum to EMA/CHMP/CVMP/QWP/17760/2009 Rev 3: Defining the Scope of an NIRS Procedure
Committee for Advanced Therapies (CAT): 17-19 April 2024, European Medicines Agency, Amsterdam, the Netherlands, from 17 April 2024 to 19 April 2024
Submitted by Anonymous (not verified) on 2 May 2024 - 13:50
Committee for Advanced Therapies (CAT): 17-19 April 2024, European Medicines Agency, Amsterdam, the Netherlands, from 17 April 2024 to 19 April 2024
Herbal medicinal product: Malvae foliumArray,Array, F: Assessment finalised
Submitted by Anonymous (not verified) on 2 May 2024 - 13:35
Herbal medicinal product: Malvae foliumArray,Array, F: Assessment finalised
FDIME-EFIM 19th CLINICAL RESEARCH SEMINAR
Submitted by Aneta on 2 May 2024 - 12:10
FDIME Announces the 19th FDIME-EFIM Clinical Research Course, Paris from 9 - 11 October 2024.
Human medicines European public assessment report (EPAR): Zynyz, retifanlimab, Date of authorisation: 19/04/2024, Status: Authorised
Submitted by Anonymous (not verified) on 2 May 2024 - 11:00
Human medicines European public assessment report (EPAR): Zynyz, retifanlimab, Date of authorisation: 19/04/2024, Status: Authorised
CAT quarterly highlights and approved ATMPs - February - April 2024
Submitted by Anonymous (not verified) on 2 May 2024 - 10:11
CAT quarterly highlights and approved ATMPs - February - April 2024
Quality of medicines questions and answers: Part 1
Submitted by Anonymous (not verified) on 2 May 2024 - 8:42
Quality of medicines questions and answers: Part 1
Guideline on stability testing for applications for variations to a marketing authorisation for veterinary medicinal products
Submitted by Anonymous (not verified) on 2 May 2024 - 8:25
Guideline on stability testing for applications for variations to a marketing authorisation for veterinary medicinal products